Stay updated with breaking news from Decipher Prostate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Veracyte, Inc. , a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance for prostate...
Veracyte, Inc. , a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in...
Veracyte, Inc. misses on earnings expectations. Reported EPS is $-0.39 EPS, expectations were $-0.07. Veracyte, Inc.
Grew Fourth Quarter Revenue to $98.2 million Increased 2023 Total Revenue 22% to $361.1 million Conference Call and Webcast Today at 4:30 p.m. ET ...
Veracyte, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2023. "We closed 2023 with another quarter of excellent results, driven by our Afirma and Decipher businesses," said Marc Stapley, Veracyte's...